Holen Sie sich die Stockscreener-App
3.07
3.15%
-0.10
Schlusskurs vom Vortag:
$3.17
Offen:
$3.17
24-Stunden-Volumen:
711.39K
Relative Volume:
0.51
Marktkapitalisierung:
$1.04B
Einnahmen:
$787.89M
Nettoeinkommen (Verlust:
$20.56M
KGV:
52.48
EPS:
0.0585
Netto-Cashflow:
$96.54M
1W Leistung:
+3.72%
1M Leistung:
+6.60%
6M Leistung:
+35.24%
1J Leistung:
-35.91%
1-Tages-Spanne:
$3.06
$3.17
1-Wochen-Bereich:
$2.9608
$3.305
52-Wochen-Spanne:
$1.77
$5.8099
Goodrx Holdings Inc Stock (GDRX) Company Profile
Firmenname
Goodrx Holdings Inc
Sektor
Branche
Telefon
(855) 268-2822
Adresse
2701 OLYMPIC BOULEVARD, SANTA MONICA
Compare GDRX vs VEEV, BTSG, HQY, TEM, TXG
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GDRX
Goodrx Holdings Inc
|
3.07 | 1.03B | 787.89M | 20.56M | 96.54M | 0.0585 |
VEEV
Veeva Systems Inc
|
203.77 | 31.59B | 3.32B | 941.65M | 1.64B | 5.6161 |
BTSG
Brightspring Health Services Inc
|
59.74 | 14.13B | 13.65B | 169.86M | 412.12M | 1.0758 |
HQY
Healthequity Inc
|
100.61 | 8.28B | 1.34B | 230.70M | 440.96M | 2.6695 |
TEM
Tempus Ai Inc
|
43.87 | 7.73B | 1.36B | -302.91M | -219.93M | -1.7182 |
TXG
10 X Genomics Inc
|
47.27 | 5.83B | 638.78M | -22.66M | 122.18M | -0.1744 |
Goodrx Holdings Inc Stock (GDRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-27 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2026-01-22 | Herabstufung | Jefferies | Buy → Hold |
| 2025-12-09 | Eingeleitet | Barclays | Underweight |
| 2025-08-11 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2024-12-04 | Eingeleitet | Mizuho | Neutral |
| 2024-08-09 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-05-23 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-05-16 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2024-04-10 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2024-03-25 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-03-01 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-02-26 | Eingeleitet | Leerink Partners | Outperform |
| 2024-01-02 | Herabstufung | BofA Securities | Buy → Underperform |
| 2023-08-10 | Hochstufung | DA Davidson | Neutral → Buy |
| 2023-07-31 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2022-12-01 | Eingeleitet | Citigroup | Buy |
| 2022-11-04 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2022-09-16 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2022-09-07 | Eingeleitet | Truist | Hold |
| 2022-08-12 | Eingeleitet | DA Davidson | Neutral |
| 2022-06-10 | Herabstufung | Goldman | Buy → Neutral |
| 2022-06-06 | Fortgesetzt | BofA Securities | Buy |
| 2022-06-01 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2022-05-10 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-05-10 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-05-10 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-05-10 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-04-11 | Eingeleitet | Wells Fargo | Equal Weight |
| 2022-04-07 | Eingeleitet | Guggenheim | Buy |
| 2022-04-01 | Fortgesetzt | Credit Suisse | Neutral |
| 2022-03-15 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-03-01 | Bestätigt | Barclays | Overweight |
| 2022-03-01 | Bestätigt | BofA Securities | Neutral |
| 2022-03-01 | Herabstufung | Cowen | Outperform → Market Perform |
| 2022-03-01 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-03-01 | Bestätigt | Evercore ISI | Outperform |
| 2022-03-01 | Bestätigt | Goldman | Buy |
| 2022-03-01 | Bestätigt | JP Morgan | Underweight |
| 2022-03-01 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-03-01 | Bestätigt | SVB Leerink | Outperform |
| 2022-01-07 | Eingeleitet | Goldman | Buy |
| 2021-12-21 | Eingeleitet | Stephens | Overweight |
| 2021-12-02 | Eingeleitet | Jefferies | Buy |
| 2021-08-31 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2021-08-13 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2021-05-28 | Eingeleitet | Robert W. Baird | Neutral |
| 2021-04-06 | Fortgesetzt | Evercore ISI | Outperform |
| 2021-01-25 | Eingeleitet | Guggenheim | Buy |
| 2020-11-19 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-10-19 | Eingeleitet | Barclays | Equal Weight |
| 2020-10-19 | Eingeleitet | BofA Securities | Neutral |
| 2020-10-19 | Eingeleitet | Citigroup | Buy |
| 2020-10-19 | Eingeleitet | Cowen | Outperform |
| 2020-10-19 | Eingeleitet | Credit Suisse | Outperform |
| 2020-10-19 | Eingeleitet | Deutsche Bank | Hold |
| 2020-10-19 | Eingeleitet | Goldman | Neutral |
| 2020-10-19 | Eingeleitet | JP Morgan | Neutral |
| 2020-10-19 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-10-19 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2020-10-19 | Eingeleitet | SVB Leerink | Outperform |
| 2020-10-19 | Eingeleitet | UBS | Buy |
Alle ansehen
Goodrx Holdings Inc Aktie (GDRX) Neueste Nachrichten
GoodRx Holdings Inc (GDRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
GoodRx Holdings Inc (GDRX) Valuation: PE, PB & Fair Value Analysis - TradingKey
GDRX|GoodRx Holdings Inc|Price:3.065|Chg%:+0.105 - TradingKey
GoodRx Holdings Inc (GDRX) Income Statement - TradingKey
GoodRx Holdings Inc (GDRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
GoodRx Holdings Inc (GDRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
GoodRx Holdings Inc (GDRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
GoodRx Holdings Inc (GDRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
GoodRx Holdings Inc (GDRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
GoodRx Holdings Inc (GDRX) Institutional Confidence - TradingKey
Teladoc, GoodRx shares fall on OpenAI health feature launch By Investing.com - Investing.com Australia
GoodRx (GDRX) Receives Positive Analyst Outlook with $4 Price Ta - GuruFocus
GoodRx (GDRX): Buy, Sell, or Hold Post Q1 Earnings? - Yahoo Finance
GoodRx Holdings, Inc. (GDRX) Stock Analysis: Navigating Healthcare with a 1.30% Upside Potential - DirectorsTalk Interviews
GoodRx Holdings (GDRX) Posts Modest Gain as Stock Hovers Near SupportTurnaround Stocks - po-news-eg.net
Thomas (tc) Chan Net Worth (2026) - GuruFocus
GoodRx Holdings Inc (FRA:8GH) Stock Price, Trades & News - GuruFocus
Form 4 Goodrx Holdings Inc For: 16 July By Investing.com - Investing.com Nigeria
GoodRx Holdings (GDRX) officer exercises RSUs, withholds shares for taxes - Stock Titan
GoodRx Holdings (NASDAQ: GDRX) insider converts RSUs, covers tax with stock - Stock Titan
GoodRx (GDRX) CAO exercises RSUs and withholds shares for taxes - Stock Titan
Frontier tech research, news & data - MLQ.ai
GoodRx (GDRX) Q4 2025 earnings summary - Quartr
GDRX Q1 2026 Earnings: EPS Misses Estimates, Stock Gains on ResilienceProfitability Analysis - dars.gov.et
GDRX or HQY: Which is the better value stock right now? - MSN
GoodRx (GDRX) Stock Trades Up, Here Is Why - Yahoo Finance
GoodRx Holdings (GDRX) Pharma Growth Story Meets A Small Fair Value Gap - Yahoo Finance
GoodRx (GDRX) Stock Looks Full On Earnings But Mixed On Value - Yahoo Finance
GoodRx (GDRX) Q1 2025 earnings summary - Quartr
GoodRx sets date for Q2FY26 earnings release - scanx.trade
Press Release: GoodRx Announces Date for Second Quarter 2026 Earnings Release and Conference Call - Moomoo
GoodRx sets Aug. 5 earnings release, Aug. 6 call - Stock Titan
GoodRx Announces Date for Second Quarter 2026 Earnings Release and Conference Call - Business Wire
GoodRx (GDRX) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
GDRX or HQY: Which Is the Better Value Stock Right Now? - Yahoo Finance
Is GoodRx (GDRX) Stock Undervalued Right Now? - Yahoo Finance
Earnings call transcript: GoodRx Q1 2026 revenue exceeds forecasts - Investing.com
GDRXGoodRx Holdings Inc Options - Finviz
GDRX.O - Reuters
3 Penny Stocks Under $8B Market Cap Worth Watching - simplywall.st
Enterprise value to revenue forward of GoodRx Holdings, Inc. – NASDAQ:GDRX - TradingView
GoodRx Holdings Inc (GDRX) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Enterprise value to revenue forward of GoodRx Holdings, Inc. – BOATS:GDRX - TradingView
Price to sales forward of GoodRx Holdings, Inc. – NASDAQ:GDRX - TradingView
Price to sales forward of GoodRx Holdings, Inc. – BOATS:GDRX - TradingView
GoodRx Holdings, Inc. Class A Actuals & Estimates (NASDAQ:GDRX) - TradingView
Enterprise value to EBITDA forward of GoodRx Holdings, Inc. – BOATS:GDRX - TradingView
GDRX Forecast — Price Target — Prediction for 2027 - TradingView
Price to book forward of GoodRx Holdings, Inc. – BOATS:GDRX - TradingView
Enterprise value to EBIT forward of GoodRx Holdings, Inc. – NASDAQ:GDRX - TradingView
Price to earnings forward of GoodRx Holdings, Inc. – NASDAQ:GDRX - TradingView
Finanzdaten der Goodrx Holdings Inc-Aktie (GDRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Goodrx Holdings Inc-Aktie (GDRX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| REY-GIRAUD AGNES | Director |
Mar 12 '26 |
Option Exercise |
0.47 |
192,185 |
90,327 |
277,633 |
| Spectrum Equity VII, L.P. | 10% Owner |
Oct 15 '25 |
Sale |
4.00 |
23,771 |
95,103 |
0 |
0.84%
0.79%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):